Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This study compares the efficacy and effectiveness of two of the second-generation
antipsychotics (SGAs) most used in our society in the treatment of schizophrenia
(Aripiprazole and Risperidone) and the investigators do within an assistance program of
early-stage psychosis individuals of the Community of Cantabria, clinical reference for the
treatment of this disease in the Spanish Autonomous Community. Patients are included in a
prospective naturalistic study, open flexible-doses and randomized into one of two possible
patterns of treatment that includes the protocol.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación Marques de Valdecilla
Collaborators:
Centro de Investigación Biomédica en Red de Salud Mental Instituto de Investigación Marqués de Valdecilla